Works by Yang, Yuanxun

Results: 14

Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4220, doi. 10.1111/dom.16452

By:

Wang, Qinghua;
Cui, Qiaoli;
Xu, Yulong;
Prud'homme, Gerald J.;
Yang, Yuanxun;
Zhu, Dalong;
Li, Yiming;
Yang, Yehong;
Li, Juan

Publication type:

Article

Automatic Fabric Defect Detection Method Using AC-YOLOv5.

Published in:

Electronics (2079-9292), 2023, v. 12, n. 13, p. 2950, doi. 10.3390/electronics12132950

By:

Guo, Yongbin;
Kang, Xinjian;
Li, Junfeng;
Yang, Yuanxun

Publication type:

Article

Pharmacokinetic and Bioequivalence Evaluation of Single‐Tablet and Separate‐Tablet Regimens for Ainuovirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Chinese Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 70, doi. 10.1002/cpdd.1309

By:

Huang, Lei;
Lei, Jing;
Yang, Yuanxun;
Ma, Tingting;
Lin, Hui;
Cao, Bei;
Li, Juan

Publication type:

Article

Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.

Published in:

BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03394-z

By:

Lin, Diaozhu;
Xiao, Huisheng;
Yang, Kexu;
Li, Juan;
Ye, Suiwen;
Liu, Yanqiong;
Jing, Shan;
Lin, Yang;
Yang, Yuanxun;
Huang, Lei;
Yuan, Jing;
Li, Ziyan;
Yang, Jinlan;
Gao, Huanhuan;
Xie, Ying;
Xu, Mingtong;
Yan, Li

Publication type:

Article

ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-84050-7

By:

Ma, Hehua;
Hong, Yuxin;
Xu, Zhenzhen;
Weng, Zuyi;
Yang, Yuanxun;
Jin, Dandan;
Chen, Zhiyou;
Zhou, Xuan;
Xu, Zhi;
Fei, Fei;
Song, Wei;
Li, Juan

Publication type:

Article

The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects.

Published in:

Expert Opinion on Investigational Drugs, 2024, v. 33, n. 10, p. 1075, doi. 10.1080/13543784.2024.2391837

By:

Ma, Tingting;
Weng, Zuyi;
Cao, Bei;
Dong, Yanli;
Deng, Chanjuan;
Huang, Lei;
Yang, Yuanxun;
Wang, Yuqi;
Shen, Chenxi;
Wang, Lei;
Shen, Kai;
Li, Juan

Publication type:

Article

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 289, doi. 10.1007/s10637-024-01436-0

By:

Cao, Bei;
Ma, Tingting;
Zhang, Yuqiang;
Huang, Lei;
Lin, Hui;
Jiang, Huanhuan;
Zhao, Yu;
Geng, Yan;
Yang, Yuanxun;
Cao, Sumin;
Li, Juan

Publication type:

Article

Metabolomics analysis reveals cytotoxic effects of ouabain towards psoriatic keratinocytes via impairment of glutathione metabolism.

Published in:

Molecular Genetics & Genomics, 2023, v. 298, n. 3, p. 567, doi. 10.1007/s00438-023-02001-9

By:

Zhou, Xuan;
Fei, Fei;
Song, Wei;
Ma, Hehua;
Xu, Zhenzhen;
Yue, Jing;
Cao, Bei;
Sun, Runbin;
Zhao, Yu;
Yang, Yuanxun;
Jiang, Junyi;
Geng, Yan;
Weng, Zuyi;
Li, Juan

Publication type:

Article

ALKBH5-mediated N<sup>6</sup>-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation.

Published in:

Cell Death Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41420-022-00819-7

By:

Song, Wei;
Fei, Fei;
Qiao, Fengchang;
Weng, Zuyi;
Yang, Yuanxun;
Cao, Bei;
Yue, Jing;
Xu, Jiaxuan;
Zheng, Meihong;
Li, Juan

Publication type:

Article

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 01, doi. 10.3389/fphar.2022.1075309

By:

Tingting Ma;
Bei Cao;
Lei Huang;
Yuanxun Yang;
Yan Geng;
Pinhao Xie;
Yu Zhao;
Hui Lin;
Kun Wang;
Chunhe Wang;
Runbin Sun;
Juan Li

Publication type:

Article

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.1027627

By:

Tingting Ma;
Yanli Dong;
Lei Huang;
Yuanxun Yang;
Yan Geng;
Fei Fei;
Pinhao Xie;
Yu Zhao;
Hui Lin;
Zeyu Yang;
Yun Jin;
Xitong Ju;
Runbin Sun;
Juan Li

Publication type:

Article

Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.

Published in:

Expert Opinion on Drug Metabolism & Toxicology, 2023, v. 19, n. 9, p. 653, doi. 10.1080/17425255.2023.2260738

By:

Cao, Bei;
Huang, Lei;
Liu, Ming;
Lin, Hui;
Ma, Tingting;
Zhao, Yu;
Geng, Yan;
Yang, Yuanxun;
Guo, Haifang;
Li, Juan

Publication type:

Article

The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of singleand multiple-ascending doses.

Published in:

Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1327008

By:

Yuanxun Yang;
Lei Yu;
Zejuan Sheng;
Hui Lin;
Zuyi Weng;
Wei Song;
Bei Cao;
Yu Zhao;
Yingsheng Gao;
Shumao Ni;
Huimin Wang;
Tingting Ma;
Lei Huang;
Caixia Sun;
Juan Li

Publication type:

Article

Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.

Published in:

Frontiers in Endocrinology, 2025, p. 1, doi. 10.3389/fendo.2025.1487058

By:

Yang, Haoyi;
Zhang, Yuwen;
Hong, Yuxin;
Wei, Yuan;
Zhu, Yuning;
Huang, Lei;
Yang, Yuanxun;
Sun, Runbin;
Li, Juan

Publication type:

Article